VCARE PHARMATECH

Jiangsu Vcare PharmaTech Co., Ltd.(Jiangsu Vcare), established in 2010, is a high-tech biopharmaceutical company dedicated to addressing unmet clinical needs through differentiated innovation in drug and advanced therapy development. Since our inception, we’ve experienced rapid growth and evolved into a group-style enterprise with a strong foundation in two core business segments: innovative drug R&D and comprehensive pharmaceutical industry chain services. With 15 years of experience and a forward-looking mindset, Jiangsu Vcare continues to shape the future of biopharma through technology, quality, and purpose-driven innovation.

Learn More →

INNOVATIVE DRUGS

Jiangsu Vcare's proprietary innovative drug R&D business adheres to a differentiated strategy addressing unmet clinical needs. Based on innovative approaches including "overcoming therapeutic resistance", "resolving drug resistance", and "enhancing target selectivity", the company has established a tiered pipeline architecture centered on Vicagrel. Currently, it possesses five Class I innovative drugs in clinical development: VC004 capsules (oral anti-tumor targeted therapy); Vicagrel capsules (oral anti-thrombotic agent); VC005 tablets (oral immunomodulatory and anti-inflammatory agent); VC005 gel (topical immunomodulatory and anti-inflammatory formulation). Additionally, multiple preclinical projects are progressing through the pipeline, with therapeutic focuses spanning cardiovascular/cerebrovascular diseases, oncology, and autoimmune/inflammatory disorders. This strategic portfolio positions the company for comprehensive coverage of global pharmaceutical markets in the future.

INNOVATION PLATFORM

Innovative Drugs - Medicine - Pharmacy - Chemistry; Covering The Entire Life Cycle Of New Drug Research And Development

Learn More →

NEWS

New Progress in Autoimmune Disease Pipeline! Vcare PharmaTech's VC005 Topical Gel Secures China IND Approval for Plaque Psoriasis

2026-06-12

Recently, VC005 topical gel, a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), has officially obtained the IND approval from the CDE for the topical treatment of plaque psoriasis.

Vcare PharmaTech Enters into Exclusive Licensing Agreement with Everest Medicines for Sumecigrel Across Multiple Asia-Pacific Countries and Regions

2026-06-09

9 June 2026 – Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech，Company), a commercial-stage innovative biopharmaceutical firm leveraging AI for differentiated original drug design, today announced the signing of an exclusive licensing agreement with Everest Medicines (HKEX: 1952.HK). Under the deal, Vcare PharmaTech grants Everest Medicines exclusive rights for the clinical development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across multiple Asia-Pacific countries and regions (including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR and Taiwan region of China).

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

2026-06-05

On June 4, the official website of the NMPA announced that Vcare PharmaTech’s Class 1 new drug, Eratrectinib (VELMARTO®), has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions.

Company Address:

No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China

Subsidiary NJVcare Website：

en.njvcare.com

Scan to see

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

SEO

Powerby：www.300.cn nanjing.300.cn